Tyrosine kinase inhibitors (TKI), molecular-targeted drugs, inhibit specific oncogenic drivers, such as the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), which trigger cancer evolution. The gene discussed is ALK; the disease is cancer.